Boston Scientific

Boston Scientific Liabilities

The The Liabilities of Boston Scientific (BSX) as of Oct 17, 2026 is 19.20 B USD. In the previous year, The Liabilities was 17.39 B USD — a change of 10.40% (higher).

Liabilities

19.20 BUSD

YoY

10.40%

Last updated:

In 2025, Boston Scientific's total liabilities amounted to 19.20 B USD, a 10.40% difference from the 17.39 B USD total liabilities in the previous year.

The Boston Scientific Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
12.27 B USD
Jan 1, 2019
16.69 B USD
Jan 1, 2020
15.45 B USD
Jan 1, 2021
15.61 B USD
Jan 1, 2022
14.90 B USD
Jan 1, 2023
15.61 B USD
Jan 1, 2024
17.39 B USD
Jan 1, 2025
19.20 B USD
The Boston Scientific Liabilities history
YEARLiabilitiesYoY
19.20 BUSD+10.40%
17.39 BUSD+11.44%
15.61 BUSD+4.77%
14.90 BUSD-4.56%
15.61 BUSD+1.01%
15.45 BUSD-7.41%
16.69 BUSD+35.97%
12.27 BUSD+2.02%
12.03 BUSD+5.87%
11.36 BUSD-3.81%
11.81 BUSD+18.28%
9.99 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Boston Scientific Stock analysis

What does Boston Scientific do? Boston Scientific Corp. is a global medical technology company specializing in the development and manufacturing of innovative solutions for medical challenges and needs. The company was founded in 1979 and has since been dedicated to meeting the individual needs of patients and medical professionals with innovative products. The history of Boston Scientific began in the 1960s when French engineer Jean-Marc Simon started developing pacemakers at the University of Minnesota. In 1969, Medtronic acquired Simon's pacemaker development, leading to the founding of Boston Scientific. From the beginning, the company focused on the production of cardiovascular implants, including pacemakers, implanted defibrillators, and stents. In the following years, the company achieved continued growth through acquisitions of competitors and advancements in research and development, particularly in the field of minimally invasive procedures. Today, Boston Scientific is a globally leading provider of innovative medical devices and solutions used in various areas of healthcare. Boston Scientific's business model is based on meeting the needs of patients, medical professionals, and healthcare policymakers in order to improve healthcare. The company works closely with doctors, hospitals, nursing facilities, and research institutions to continuously develop innovative solutions for various diseases and conditions. Boston Scientific has five business segments: Cardiovascular Systems, Interventional Oncology and Neuromodulation, Urology and Women's Health, Medical Oncology, and Endoscopy. The Cardiovascular Systems segment includes products and solutions for cardiovascular surgery, including pacemakers, implanted defibrillators, and catheters. The company is also involved in endovascular surgery, offering innovative stent and catheter systems for the treatment of aneurysms and arterial occlusive disease. The Interventional Oncology and Neuromodulation segment includes solutions for the minimally invasive treatment of cancer and chronic pain through catheter and implant systems. For example, Boston Scientific offers intensity-controlled radiofrequency ablation and neuromodulation procedures. The Urology and Women's Health segment includes products for the treatment and diagnosis of urogenital system disorders, including incontinence, urinary incontinence, and genital diseases. Boston Scientific offers innovative solutions for women, such as the treatment of urinary incontinence or the removal of uterine fibroids. The Medical Oncology segment includes products for the diagnosis and treatment of cancer, including in vitro diagnostics and novel treatments such as chemotherapy delivery technology. The Endoscopy segment includes endoscopic solutions, including the diagnosis and therapy of digestive tract, chest, and lung disorders. Boston Scientific's product portfolio is diverse and includes numerous innovative medical devices and systems designed to meet the needs of patients and medical professionals. Some of the notable products of the company include: - The Implantable Cardioverter-Defibrillator (ICD) is an innovative device that can treat heart rhythm disorders through the use of a remote control. - Drug-Eluting Stents are stents that deliver medication directly at the site of narrowing, promoting blood flow and helping to keep the artery open. - The Synergy is a top-of-the-line stent that has both a lower mortality rate and a higher success rate than conventional stents. - The Venus-EP Steerable Sheath is an advanced catheter that allows physicians unique navigation within the heart chambers. - The Precision is a catheter that sends impulses to the heart for the diagnosis and treatment of atrial fibrillation. - The Transcend is a pacemaker that combines traditional pacemaker function with a sensor that actively supports the patient during physical activity. - The Symphion is an innovative system for laparoscopic surgery that enables minimally invasive surgical procedures in women. In conclusion, Boston Scientific Corp. is a globally leading provider of innovative medical devices and solutions that run like a common thread through its various business segments. With a significant focus on research and development, the company offers a wide range of products to ensure that patients worldwide have access to innovative medical care. Through pioneering innovations, the development of new technologies, and collaboration with medical professionals, Boston Scientific will continue to defend its position as a leading provider of medical solutions worldwide. Boston Scientific is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Boston Scientific's Liabilities

Boston Scientific's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Boston Scientific's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Boston Scientific's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Boston Scientific's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Boston Scientific’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Boston Scientific stock

The Liabilities of Boston Scientific is 19.20 B USD in 2025.

The Liabilities of Boston Scientific changed from 17.39 B USD to 19.20 B USD, representing a 10.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Boston Scientific since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Boston Scientific historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Boston Scientific

All Key Metrics — Boston Scientific